Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Completed · Phase 3 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise. Secondary Objectives: * To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on glycemic control * To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on body weight * To evaluate the safety of once-weekly injection of efpeglenatide

Key facts

Study ID

NCT03353350

Run by

Hanmi Pharmaceutical Company Limited

People needed

406

Starts

2017-12-05

Expected to finish

2020-09-07

Last updated by the study team

2022-01-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must be at least 18 years of age at the time of signing the informed consent.
• Participants with T2DM, and treated with diet and exercise.
• Hemoglobin A1c between 7.0% and 10.0% (inclusive) measured by the central laboratory at Screening.

You may not qualify if…

• Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to) gastroparesis, unstable and not controlled gastroesophageal reflux disease within 6 months prior to Screening or history of surgery affecting gastric emptying.
• History of pancreatitis (unless pancreatitis was related to gallstone and cholecystectomy has been performed) and pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, and pancreatectomy.
• Personal or family history of Medullary Thyroidian Cancer (MTC) or genetic conditions that predisposes to MTC (eg multiple endocrine neoplasia syndromes).
• Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months of screening) or planned: intravitreal injections or laser or vitrectomy surgery.
• Body weight change of ≥5 kg within the last 3 months prior to Screening.
• Systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg at Randomization.
• End-stage renal disease as defined by estimated glomerular filtration rate (eGFR , by Modification of Diet in Renal Disease [MDRD]) of <15 mL/min/1.73 m2.
• Laboratory findings at the Screening Visit:
• Alanine aminotransferase (ALT ) or aspartate aminotransferase (AST ) >3 times the upper limit of the normal (ULN ) or total bilirubin >1.5 times the ULN (except in case of documented Gilbert's syndrome).
• Amylase and/or lipase: >3 times the ULN laboratory range.
• Calcitonin ≥5.9 pmol/L (20 pg/mL).
• Gastric surgery or other gastric procedures intended for weight loss within 2 years prior to Screening, or planned during study period.
• History of drug or alcohol abuse within 6 months prior to the time of Screening.
• Pregnant (demonstrated by serum pregnancy test at Screening) or breast-feeding women.
• Women of childbearing potential not willing to use highly effective method(s) of birth control during the study period and for at least 5 weeks after the last dose of study intervention.
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Investigational Site Number 8400005 — Glendale, Arizona, United States
• Investigational Site Number 8400003 — Canoga Park, California, United States
• Investigational Site Number 8400007 — Chula Vista, California, United States
• Investigational Site Number 8400011 — La Mesa, California, United States
• Investigational Site Number 8400009 — Los Angeles, California, United States
• Investigational Site Number 8400029 — Pomona, California, United States
• Investigational Site Number 8400024 — Tarzana, California, United States
• Investigational Site Number 8400026 — Van Nuys, California, United States
• Investigational Site Number 8400010 — DeLand, Florida, United States
• Investigational Site Number 8400006 — Hialeah, Florida, United States
• Investigational Site Number 8400032 — West Palm Beach, Florida, United States
• Investigational Site Number 8400025 — Lawrenceville, Georgia, United States
• Investigational Site Number 8400034 — Chicago, Illinois, United States
• Investigational Site Number 8400033 — Kansas City, Missouri, United States
• Investigational Site Number 8400018 — Lincoln, Nebraska, United States
• Investigational Site Number 8400062 — Las Vegas, Nevada, United States
• Investigational Site Number 8400021 — Las Vegas, Nevada, United States
• Investigational Site Number 8400001 — Bridgeton, New Jersey, United States
• Investigational Site Number 8400028 — Burlington, North Carolina, United States
• Investigational Site Number 8400031 — Wilmington, North Carolina, United States
• Investigational Site Number 8400013 — Maumee, Ohio, United States
• Investigational Site Number 8400008 — Hatboro, Pennsylvania, United States
• Investigational Site Number 8400017 — Carrollton, Texas, United States
• Investigational Site Number 8400030 — Dallas, Texas, United States
• Investigational Site Number 8400004 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.